Trials / Recruiting
RecruitingNCT07221877
A Study to Evaluate the Effect of KarXT on Urological Safety
A 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xanomeline/trospium chloride | Specified dose on specified days |
Timeline
- Start date
- 2026-01-20
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
- First posted
- 2025-10-28
- Last updated
- 2026-04-01
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07221877. Inclusion in this directory is not an endorsement.